Meeting
2014 Genitourinary Cancers Symposium
Biochemical response to ketoconazole therapy in post-chemotherapy mCRPC patients.
Authors
M. Andreas Roeder
Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen, Denmark
M. Andreas Roeder , Kasper Drimer Berg , Daniel Hunde , Camilla Nerstroem , Frederik Birkebæk Thomsen , Klaus Brasso , Peter Iversen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 174)
DOI
10.1200/jco.2014.32.4_suppl.174
Abstract #
174
Poster Bd #
K17
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2014 Genitourinary Cancers Symposium
Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.
First Author: Evan Y. Yu
Poster
2024 ASCO Genitourinary Cancers Symposium
The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail M. Al-Ezzi
Poster
2022 ASCO Annual Meeting
Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.
First Author: Nicholas D. James